BSEAptus Pharma LtdMediumNeutral
Announced Sat, 27 Jun · 13:40 IST

CARE Ratings assigns BB Stable issuer rating to Aptus Pharma

Rating JunkCredit & Debt View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-3.7%1-day move
₹235.15
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-3.7-2.2-0.5-0.4-2.5-4.4+6.3
Up moveDown movePending
AI summary

CARE Ratings assigned a CARE BB with Stable outlook issuer rating to Aptus Pharma Limited on June 26, 2026, a first-time rating. Aptus is a Gujarat-based pharma marketing and distribution firm listed on BSE SME since September 2025. FY26 revenue jumped about 90 percent to Rs 46.57 crore with PBILDT margin of around 16 percent. The rating is constrained by modest scale, working capital intensity, stretched liquidity, geographic concentration and dependence on contract manufacturers. Strengths include experienced promoter and comfortable capital structure post IPO with gearing at 0.31x.

Likely market impact

CARE BB is a below investment grade (speculative) rating. Stable outlook and improving post IPO financials are positives, but small scale and stretched liquidity remain concerns.